David Rolfe (Trades, Portfolio) recently submitted the 13F filing for the second quarter of 2025, providing insights int ...

Zoetis’ second quarter saw revenue and adjusted earnings surpass Wall Street expectations, but the market responded ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and ...

From supporting identification of certain cell characteristics to complementing clinical expertise with remote pathologist ...

Animal health company Zoetis (NYSE:ZTS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.2% ...

Meanwhile, the company has an impeccable dividend program. The company has increased its payouts by 502% over the past decade ...

Zoetis Inc. Q2 2025 earnings highlight 8% organic revenue growth, raised guidance, and strong performance from Simparica and Key Dermatology franchises.

Zoetis beats Q2 estimates with strong pet product sales and raises full-year guidance despite livestock sales decline and Librela weakness.

Zoetis (ZTS) stock surges premarket as the company posts strong Q2 2025 results and raises full-year outlook. Read more here.

Delve into the growing cat-focused biotech landscape. Cats are the second most adopted pets and biotech is making their lives ...

The company raised its full-year 2025 guidance, now expecting revenue between $9.45 billion and $9.6 billion, representing ...

Breed Explorer offers veterinarian-approved, science-backed insights to help current and prospective pet owners make informed ...